Quinethazone | CAS# 73-49-4 | Thiazide Diuretic

Quinethazone
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318601

CAS#: 73-49-4

Description: Quinethazone is a thiazide diuretic used to treat hypertension. Common side effects include dizziness, dry mouth, nausea, and low potassium levels.

Chemical Structure

Quinethazone

CAS# 73-49-4

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 318601
Name: Quinethazone
CAS#: 73-49-4
Chemical Formula: C10H12ClN3O3S
Exact Mass: 289.03
Molecular Weight: 289.740
Elemental Analysis: C, 41.45; H, 4.17; Cl, 12.24; N, 14.50; O, 16.57; S, 11.07

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 950
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Quinethazone; Chinethazonum; Quinethazon; Quinethazonum; Aquamox; Hydromox; quinethazone, (+)-isomer; quinethazone, (+-)-isomer; quinethazone, (-)-isomer;

IUPAC/Chemical Name: 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide

InChi Key: AGMMTXLNIQSRCG-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)

SMILES Code: CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: TBD

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Certificate of Analysis:

View CoA: current batch, Lot#T9R09C22

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	Quinethazone inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Quinethazone also inhibits sodium ion transport across the renal tubular epithelium The antihypertensive mechanism of quinethazone is less well understood.
In vitro activity:	TBD
In vivo activity:	The additive natriuretic effects of single doses of quinethazone or bendroflumethiazide have been studied in patients with advanced congestive heart failure receiving longterm treatment with furosemide and spironolactone daily. Since the combined effects of all three drugs involve a tendency to development of hypokalaemia, hypochloraemia and alkalosis, it is recommended that quinethazone or bendroflumethiazide use is combined with the administration of potassium chloride. Reference: Acta Medica Scandinavica, 190(3), 233–240. https://onlinelibrary.wiley.com/doi/abs/10.1111/j.0954-6820.1971.tb07423.x

Preparing Stock Solutions

The following data is based on the product molecular weight 289.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Zhang Z , Luo D , Xie J , Lin G , Zhou J , Liu W , Li H , Yi T , Su Z , Chen J . Octahydrocurcumin, a final hydrogenated metabolite of curcumin, possesses superior anti-tumor activity through induction of cellular apoptosis. Food Funct. 2018 Apr 25;9(4):2005-2014. doi: 10.1039/c7fo02048a. PMID: 29616245. 2. Olesen, K. H., & Sigurd, B. (1971). The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Permutation trial tests in patients with congestive heart failure. Acta Medica Scandinavica, 190(3), 233–240. https://doi.org/10.1111/j.0954-6820.1971.tb07423.x
In vitro protocol:	TBD
In vivo protocol:	1. Zhang Z , Luo D , Xie J , Lin G , Zhou J , Liu W , Li H , Yi T , Su Z , Chen J . Octahydrocurcumin, a final hydrogenated metabolite of curcumin, possesses superior anti-tumor activity through induction of cellular apoptosis. Food Funct. 2018 Apr 25;9(4):2005-2014. doi: 10.1039/c7fo02048a. PMID: 29616245. 2. Olesen, K. H., & Sigurd, B. (1971). The supra-additive natriuretic effect addition of quinethazone or bendroflumethiazide during long-term treatment with furosemide and spironolactone. Permutation trial tests in patients with congestive heart failure. Acta Medica Scandinavica, 190(3), 233–240. https://doi.org/10.1111/j.0954-6820.1971.tb07423.x

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Olesen KH, Sigurd B. The supra-additive natriuretic effect addition of
quinethazone or bendroflumethiazide during long-term treatment with furosemide
and spironolactone. Permutation trial tests in patients with congestive heart
failure. Acta Med Scand. 1971 Sep;190(3):233-40. PubMed PMID: 4941227.

2: Olesen KH, Dupont B, Flensted-Jensen E. The combined diuretic action of
quinethazone and furosemide in congestive heart failure. A permutation trial
test. Acta Med Scand. 1970 Jan-Feb;187(1-2):33-40. PubMed PMID: 4912468.

3: Trifunović S, Stamenković Z. [The use of quinethazone in the treatment of
cardiac edema]. Med Glas. 1966 Jul;20(7):246-8. Serbian. PubMed PMID: 5986856.

4: Merker W, Bauer HR. [Quinethazone and acetazolamide in edematous diseases].
Med Klin. 1966 May 13;61(19):764-8. German. PubMed PMID: 5988324.

5: Angelopoulos B, Vlassopoulos C, Kalos A. Experimental investigation and
observations on the diuretic action of quinethazone. Med Pharmacol Exp Int J Exp
Med. 1966;14(6):528-36. PubMed PMID: 6012607.

6: Naik BK, Rao PS, Saboo RM, Parlay K. Clinical trial of Quinethazone--Reserpine
(diuretic cum antihypertensive--drug). J Assoc Physicians India. 1965
Aug;13(8):637-41. PubMed PMID: 5825030.

7: Baur M. [Pharmacologic-clinical tests of new diuretics. 1. Quinethazone].
Arzneimittelforschung. 1965 Jul;15(7):806-12. German. PubMed PMID: 5324710.

8: Diamond S, Feldman E. [Treatment of essential hypertension with quinethazone
and reserpine]. Hospital (Rio J). 1965 Jul;68(1):83-8. Portuguese. PubMed PMID:
5322319.

9: Kozma JJ. [Use of quinethazone combined with reserpine in hypertension]. Folha
Med. 1965 Jun;50(6):413-7. Portuguese. PubMed PMID: 5850507.

10: Rognoni M, Guevara F, Brown A. [Quinethazone (Aquamox Lederle)]. Arch Med
Panamenos. 1965 Apr;14(1):17-22. Spanish. PubMed PMID: 5839433.

11: KOZMA JJ. CLINICAL EVALUATION OF QUINETHAZONE-RESERPINE COMBINATION IN
HYPERTENSION. Curr Ther Res Clin Exp. 1964 Nov;6:664-9. PubMed PMID: 14240756.

12: RIOSMOZO M. [TREATMENT OF ARTERIAL HYPERTENSION WITH QUINETHAZONE AND
QUINETHAZONE-RESERPINE]. Hisp Med. 1964 Aug;21:465-83. Spanish. PubMed PMID:
14202221.

13: KLEINSCHMIDT A, LUDWIG H. [INCREASED NATRIURESIS BY MEANS OF A DIURETIC
COMBINATION (QUINETHAZONE-ACETAZOLAMIDE)]. Med Klin. 1964 Jun 26;59:1063-8.
German. PubMed PMID: 14243296.

14: HUTCHEON DE, LEONARD GB, LONIEWSKI AE. BIOASSAY OF DIURETICS IN CONGESTIVE
HEART FAILURE. A COMPARISON OF QUINETHAZONE WITH HYDROCHLOROTHIAZIDE. J New
Drugs. 1964 May-Jun;4(3):148-53. PubMed PMID: 14185005.

15: HUTCHISON JC, ROEDIGER PM, WERBLIN M. CHOLESTATIC JAUNDICE FOLLOWING
ADMINISTRATION OF QUINETHAZONE. Curr Ther Res Clin Exp. 1964 Mar;6:199-201.
PubMed PMID: 14131421.

16: DIAMOND S, FELDMAN E. TREATMENT OF ESSENTIAL HYPERTENSION WITH QUINETHAZONE
PLUS RESERPINE. Curr Ther Res Clin Exp. 1964 Jan;6:62-6. PubMed PMID: 14105061.

17: FREED SC. MECHANISM OF ANTI-HYPERTENSIVE ACTION OF QUINETHAZONE. Proc Soc Exp
Biol Med. 1963 Nov;114:421-2. PubMed PMID: 14101206.

18: HALLESY DW, BENITZ KF. [TOXICITY TESTS OF QUINETHAZONE].
Arzneimittelforschung. 1963 Aug;13:665-73. German. PubMed PMID: 14085919.

19: SHIOJI T, FURUYAMA T, ABE S, SUZUKI C, MAKABE K, RIKIMARU S. [STUDIES ON
DIURETIC AND ANTIHYPERTENSIVE EFFECTS OF QUINETHAZONE]. Naika Hokan. 1963
Aug;10:397-405. Japanese. PubMed PMID: 14057126.

20: DATEY KK, PANDYA VN. QUINETHAZONE AS A DIURETIC AGENT. J Postgrad Med. 1963
Jul;9:99-105. PubMed PMID: 14066683.

Your view history

Quinethazone featured